Localized Vitiligo and Post-Inflammatory Hypopigmentation at the Injection Site of a COVID-19 mRNA Vaccine

Dora Mancha; Joana  Antunes; Luís  Soares de Almeida; João  Borges-da-Costa; Paulo Filipe

doi:10.5826/dpc.1301a23

Localized Vitiligo and Post-Inflammatory Hypopigmentation at the Injection Site of a COVID-19 mRNA Vaccine

Authors

Dora Mancha Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal
Joana Antunes Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte; Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
Luís Soares de Almeida Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte; Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa; Dermatology Research Unit, Instituto de Medicina Molecular, Universida de de Lisboa, Lisbon, Portugal
João Borges-da-Costa Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte; Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa; Dermatology Research Unit, Instituto de Medicina Molecular, Universida de de Lisboa; Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
Paulo Filipe Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte; Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa; Dermatology Research Unit, Instituto de Medicina Molecular, Universida de de Lisboa, Lisbon, Portugal

Keywords:

vitiligo, COVID-19, SARS-CoV2, mRNA, BNT162b2

References

Rijkers GT, Weterings N, Obregon-Henao A, et al. Antigen presentation of mRNA-based and virus-vectored SARS-CoV2 vaccines. Vaccines (Basel). 2021;9(8):848. DOI: 10.3390/vaccines9080848. PMID: 34451973. PMCID: PMC8402319.

McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. DOI: 10.1016/j.jaad.2021.03.092. PMID: 33838206. PMCID: PMC8024548.

Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011;36(7):708-714. DOI:10.1111/j.1365-2230.2011.04088.x. PMID: 21671990.

Aktas H, Ertuğrul G. Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence?. Clin Exp Dermatol. 2022;47(1):143-144. DOI:10.1111/ced.14842. PMID: 34236714. PMCID: PMC8444736.

Militello M, Ambur AB, Steffes W. Vitiligo Possibly Triggered by COVID-19 Vaccination. Cureus. 2022;14(1):e20902. doi: 10.7759/cureus.20902. PMID: 35145806. PMCID: PMC8809499.

Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195-197. DOI: 10.1038/s41577-021-00526-x. PMID: 33674759. PMCID: PMC7934118.

Kaminetsky J, Rudikoff D. New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination. Clin Case Rep. 2021;9(9):e04865.. DOI: 10.1002/ccr3.4865. PMID: 34603727. PMCID: PMC8465924.

Uğurer E, Sivaz O, Kıvanç Altunay İ. Newly-developed vitiligo following COVID-19 mRNA vaccine. J Cosmet Dermatol. 2022;21(4):1350-1351. DOIi:10.1111/jocd.14843. PMID: 35152540. PMCID: PMC9115282.

Ciccarese G, Drago F, Boldrin S, Pattaro M, Parodi A. Sudden onset of vitiligo after COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15196. DOI:10.1111/dth.15196. PMID: 34751491. PMCID: PMC8646249.

Lane Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004;64(4):1509-1514. DOI: 10.1158/0008-5472.can-03-3227. PMID: 14973051.